# A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

> **NCT03065959** · PHASE1 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Mobility Limitation

## Interventions

- **DRUG:** reldesemtiv
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03065959
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-28
- **Primary completion:** 2018-10-10
- **Final completion:** 2018-10-10
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Lack of efficacy determined at interim analysis
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03065959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03065959, "A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03065959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*